Brought to you by 
Saturn gets rights to Indevus's Sanctura
13 Aug 2007
Executive Summary
Indevus Pharmaceuticals (urology, infectious diseases) has signed a new exclusive US co-promotion deal for its incontinence drug Sanctura with Saturn Pharmaceuticals (urology). Indevus previously had an agreement with Pliva DD's Odyssey Pharmaceuticals division, but that deal was terminated eight months ago.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Saturn gets rights to Indevus's Sanctura
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice